David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR

Similar documents
VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Transcatheter Aortic Valve Replacement TAVR

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Percutaneous Transapical Access for Thoracic Endovascular Repair

Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation

TAVR IN INTERMEDIATE-RISK PATIENTS

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Aortic valve implantation using the femoral and apical access: a single center experience.

TAVI After PARTNER-2 : The Hamilton Approach

How to manage TAVI related vascular complications. Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI

The Role of TAVI in high-risk and normal-risk Patients

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

12-month results of a novel large access closure device: insights from the FRONTIER II Study

Is Stroke Frequency Declining?

Supplementary Online Content

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

TAVR : Caring for your patients before and after TAVR

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI: Nouveaux Horizons

(EU), FACC (USA), FSCAI (USA)

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH

TAVR in 2020: What is Next!!!!

TAVI: Transapical Procedures

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

APOLLO TMVR Trial Update: Case Presentation

Transcatheter Aortic Valve Replacement

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology

BASELINE CHARACTERISTICS. Patients (n) 62. Age (years) 77.6 ± 7.4. Male gender (%) 59.7% Weight (kg) 81.7 ± 17.4

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Using STS/ACC TVT Registry Data for Quality Improvement (QI) Learning Objectives. Overview 3/12/2014

The advent of transcatheter aortic valve implantation. Vascular Complications Among Patients. cover story

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic

Transcatheter Valve Replacement: Current State in 2017

Aortic Stenosis: Open vs TAVR vs Nothing

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Case Presentations TAVR: The Good Bad and The Ugly

Policy Specific Section: March 30, 2012 March 7, 2013

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

Outcome of elderly patients with severe but asymptomatic aortic stenosis

TAVI in Korea, How to Avoid Conduction

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

The Worshipful Company of Barbers. Mr. John Hunter. History of cardiac surgery. PDA ligation. Blalock-Taussig Shunt

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Transcatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD

Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke

Aortic Valve Stenosis and TAVR: Putting it all together.

The Role of Imaging in Transcatheter Aortic Valve Implantation

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure

Matthew R. Reynolds, M.D., M.Sc. On Behalf of the PARTNER Investigators

The Silent and Apparent Neurological Injury in Transcatheter Aortic Valve Implantation Study (SANITY)

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Transcatheter Aortic Valve Implantation Management of risks and complications

Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Current Evidence in TAVI patients using ACURATE and LOTUS valves

The Future of TAVR: Minimalist Fast Track

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

How to manage device embolization?

TAVR SPRING 2017 The evolution of TAVR

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Transcatheter aortic valve implantation and pre-procedural risk assesment

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Neuroprotection During TAVR

TAVR for low-risk patients in 2017: not so fast.

Aortic Stenosis: Background

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Indication, Timing, Assessment and Update on TAVI

e Corrado Tamburino, MD, PhD

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Transcatheter Aortic Valve Implantation Present Status and Perspectives

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Endovascular therapy for Ischemic versus Nonischemic complicated acute type B aortic dissection (catbad).

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

Transcription:

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR

TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of Complications Gender Calcification Diameter Sheath Size

How Do We Keep Track? This document provides an overview of risk assessment and patient stratification that need to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and a miscellaneous category including relevant complications not previously categorized.

VARC-2 Complications

Valve Academic Research Consortium (VARC-2) Major Complications: Aortic Dissection, Rupture, or Apical Aneurysm Access Related Vascular injury leading to death, major bleeding, ischemia, or neurologic impairment. Minor Complications: Access Related Vascular injury leading to minor bleeding. Closure device failure

What do we expect Partner Trial 15.3% major and 11.9% minor complication rates First Generation Device As devices become smaller in size injuries should become less frequent

Factors Influencing Vascular Complications Gender Calcification PAD Sheath Size a Genereux et al. J American College of Cardiology; 2014 b Toggweiler et al. J American College of Cardiology; 2012 c Barbanti et al. Eurointervention; 2013

Local Standard Of Care Sentara Heart Hospital High Volume TAVR volume with technical success and complications that are superior to the national average. If we can identify patients at risk for peripheral complications we will have a better change of prevention.

Objective This study was designed to create an iliac artery morphology score (IMS) to predict major vascular complications and procedural mortality for TAVR.

Methods Total Valve Replacements N = 341 Study criteria met N = 198 July 2011 to July 2015 Excluded: Transapical access Direct aortic access Subclavian access Inadequate CTA imaging

Outcomes and Analysis Factors found to be predictive of major complications in univariate analysis were analyzed in Presenter a multivariate name model.

Iliac Morphology Score

Conclusions An IMS composed of ipsilateral minimum iliac diameter plus iliac calcification is an excellent predictor of major vascular complications and mortality. Alternative access in patients with high IMS may reduce major vascular complications and procedural mortality.

Repair Options

Repair Options

Case study 84 year-old Caucasian male presented with SOB, chest pressure, and lightheadedness. Severe symptomatic AS with an AVA of 0.8, EF 20% in an inoperable patient due to multiple co-morbidities and frailty, prior CABG Transcatheter aortic valve replacement (TAVI) with 26 mm Sapien XT. Ascending Devices

Case study Embolized Sapiens valve Deployment of a 2nd Sapiens valve Ascending Devices

Case study CTA at 1 year TEVAR rescue with ascending aortic deployment to stabilize the valve Ascending Devices

Conclusions Operating in a hybrid OR with cardiology, cardiac surgery, vascular surgery and high quality imaging has provided excellent technical success and infrequent complications with Sentara s high volume TAVR program